| Entry |
|
|---|
| Name |
Mutation-activated RET to RAS-ERK signaling pathway
|
|---|
| Definition |
RET* -> RAS -> RAF -> MEK -> ERK |
|---|
| Expanded |
5979v2 -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595) |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Disease |
|
|---|
| Gene |
| 5979 | RET; ret proto-oncogene |
| 3265 | HRAS; HRas proto-oncogene, GTPase |
| 3845 | KRAS; KRAS proto-oncogene, GTPase |
| 4893 | NRAS; NRAS proto-oncogene, GTPase |
| 369 | ARAF; A-Raf proto-oncogene, serine/threonine kinase |
| 673 | BRAF; B-Raf proto-oncogene, serine/threonine kinase |
| 5894 | RAF1; Raf-1 proto-oncogene, serine/threonine kinase |
| 5604 | MAP2K1; mitogen-activated protein kinase kinase 1 |
| 5605 | MAP2K2; mitogen-activated protein kinase kinase 2 |
| 5594 | MAPK1; mitogen-activated protein kinase 1 |
| 5595 | MAPK3; mitogen-activated protein kinase 3 |
|
|---|
| Variant |
|
|---|
| Reference |
|
|---|
| Authors |
Giunti S, Antonelli A, Amorosi A, Santarpia L |
|---|
| Title |
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Ceolin L, Duval MADS, Benini AF, Ferreira CV, Maia AL |
|---|
| Title |
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Arighi E, Borrello MG, Sariola H |
|---|
| Title |
RET tyrosine kinase signaling in development and cancer. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
